Teva Sees Off Emergent’s US Narcan Appeal In ‘A Close Case’
‘We Are A Court Of Review, Not A Court Of First Resort,’ Federal Circuit Underlines
Shortly after agreeing to provide the state of Texas with its generic version of Emergent BioSolutions’ Narcan (naloxone) 4mg nasal spray, Teva has secured victory in patent-invalidity proceedings.
